HC Wainwright Has Optimistic Opinion of AGMB FY2026 Earnings

AgomAb Therapeutics NV (NASDAQ:AGMB) – HC Wainwright upped their FY2026 earnings estimates for AgomAb Therapeutics in a note issued to investors on Tuesday, October 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.91) per share for the year, up from their prior estimate of ($1.96). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($1.75) EPS, FY2029 earnings at ($1.81) EPS and FY2030 earnings at ($1.79) EPS.

Several other analysts also recently weighed in on the stock. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Stock Performance

Shares of AGMB stock opened at $9.26 on Friday. The company’s 50-day simple moving average is $11.60 and its two-hundred day simple moving average is $11.77. AgomAb Therapeutics has a one year low of $7.92 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter.

Insider Buying and Selling at AgomAb Therapeutics

In other AgomAb Therapeutics news, Director David Epstein bought 10,000 shares of the business’s stock in a transaction on Wednesday, October 21st. The shares were acquired at an average price of $8.88 per share, with a total value of $88,800.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $222,000. This trade represents a 66.67% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Tim Jasper Knotnerus purchased 6,000 shares of AgomAb Therapeutics stock in a transaction dated Monday, October 5th. The stock was acquired at an average price of $8.48 per share, with a total value of $50,880.00. Following the acquisition, the chief executive officer owned 16,823 shares in the company, valued at approximately $142,659.04. This represents a 55.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 41,000 shares of company stock valued at $357,080.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.